Parry J V, McAlpine L, Avillez M F
PHLS Virus Reference Laboratory, Central Public Health Laboratory, London, UK.
AIDS. 1990 Apr;4(4):355-60. doi: 10.1097/00002030-199004000-00012.
The sensitivities of six commercial combined anti-HIV-1/anti-HIV-2 enzyme immunoassays (EIAs) were evaluated, one assay (ELAVIA) based on whole virion antigen, two assays (Abbott, Wellcozyme) based on antigens expressed from recombinant DNA, and three assays (Biochrom, IAF Biochem and Pharmacia) based on synthetic peptides as antigens. All the kits investigated performed well on a panel of 47 routine anti-HIV-1-positive specimens, but on series of anti-HIV-1-seroconversion specimens from seven plasmapheresis donors, two of the peptide assays, Biochrom and Pharmacia, performed less well than the other assays. On a panel of anti-HIV-2-positive specimens, all the assays except Biochrom detected all 33 positive sera, though the reactions of some of them in the Abbott assay were relatively weak. In deciding whether to introduce a combined assay in place of an anti-HIV-1 assay, cost, specificity, the availability of confirmatory tests and the prevalence of HIV-2 in the locality, as well as sensitivity, should be considered.
评估了六种商用抗HIV-1/抗HIV-2联合酶免疫测定法（EIA）的敏感性，其中一种测定法（ELAVIA）基于全病毒体抗原，两种测定法（雅培、Wellcozyme）基于重组DNA表达的抗原，三种测定法（Biochrom、IAF Biochem和Pharmacia）基于合成肽作为抗原。所有研究的试剂盒在一组47份常规抗HIV-1阳性标本上表现良好，但在来自7名血浆置换供体的一系列抗HIV-1血清转化标本中，两种基于肽的测定法（Biochrom和Pharmacia）的表现不如其他测定法。在一组抗HIV-2阳性标本中，除Biochrom外的所有测定法都检测出了所有33份阳性血清，尽管其中一些在雅培测定法中的反应相对较弱。在决定是否引入联合测定法以取代抗HIV-1测定法时，应考虑成本、特异性、确证试验的可用性、当地HIV-2的流行率以及敏感性。
